Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus

Background Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that influences plasma levels of low-density lipoprotein cholesterol (LDL-C). Both oxidized LDL and tissue factor (TF) contributed to the development of prothrombotic state. The present study aims to explore the relationship between plasma level of PCSK9 and that of TF in patient with coronary artery disease (CAD). Methods From July 2013 to March 2014, we enrolled 197 consecutive patients who underwent coronary angiography because of suspected CAD at Beijing Anzhen Hospital in this study. All patients had no history of using lipid-lowering medication. Of these 197 patients (131 male and 66 female, mean age 56.9 ± 11.8 years), 81 had angiographically diagnosed CAD. Clinical data were collected. Plasma PCSK9 and TF were measured using enzyme-linked immunosorbent assay (ELISA). Levels of plasma PCSK9 and TF were compared and their correlation analyzed among different patient groups. Results Both plasma levels of PCSK9 (279.8 ± 60.4 µg/L vs. 216.5 ± 45.3 µg/L, P < 0.01) and TF (156.4 ± 26.6 µg/mL vs. 112.1 ± 38.3 µg/L, P < 0.01) were significantly higher in patients with CAD, as compared with those without CAD. Correlation analysis showed plasma level of PCSK9 was significantly correlated with that of TF in both patients with and without CAD. However, multivariate regression analysis after adjustment for age, gender, smoking, alcohol, hypertension and hyperlipidemia showed that only in CAD patients with type 2 diabetes mellitus, there was significant positive correlation between plasma levels of PCSK9 and TF (β = 0.353, P < 0.01). Conclusions The plasma level of PCSK9 is independently and positively associated with that of TF in CAD patients with diabetes mellitus, but not in those without diabetes mellitus. Further study is needed to investigate the underlying mechanism.

• Publication year

  2016

• Venue

  Journal of Geriatric Cardiology

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.11909/j.issn.1671-5411.2016.04.002PMID 27403140PMCID 4921543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.

  2016cited by this paper
• Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors

  2016cited by this paper
• Tissue Factor and Atherothrombosis.

  2015cited by this paper
• High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications.

  2014cited by this paper
• Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

  2014cited by this paper
• PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.

  2010cited by this paper
• A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.

  2008cited by this paper
• Unravelling the functional significance of PCSK9

  2007cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper

• PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway.

  2024cites this paper
• Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9)

  2024cites this paper
• Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with coagulation abnormalities in patients with primary membranous nephropathy

  2023cites this paper
• The Anti-Thrombotic Effects of PCSK9 Inhibitors

  2023cites this paper
• Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis

  2022cites this paper
• PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling

  2021cites this paper
• PCSK9 and atherosclerosis: Looking beyond LDL regulation

  2020cites this paper
• PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention

  2019cites this paper
• PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy

  2018cites this paper
• Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

  2018cites this paper